World’s first antibody-drug delivery system

It would be fantastic if certain crystals could be attached to the antibodies and loaded with drugs or powerful imaging agents to find the diseased cell with great precision in order to reduce the side effects on the patient.

Now, researchers at the Australian Blood Disease Center at Monash University have developed precisely this together with TU Graz (Austria).

They developed the first metal-organic structure (MOF) drug-antibody delivery system. This system has the potential to accelerate powerful new cancer therapies.

The metallo-organic structure, a mixture of metal (zinc) and carbonate ions, and a small organic molecule (an imidazole, a colorless, water-soluble solid compound) keep the payload attached to the antibody and can also be used custom data pool. therapeutic.

This advantage can become a new medical tool to target specific diseases with personalized drugs and optimized doses.

The in vitro study showed that when MOF antibody crystals bind to their target cancer cells and, if exposed to the cells’ low pH, they break down, delivering drugs directly and only to the desired area.

The results are now published in the world-renowned journal Advanced Materials.

Co-lead author Professor Christoph Hagemeyer, head of the nanobiotechnology lab at the Australian Blood Disease Center at Monash University, said. At the same time, more funding is needed to take research to the next phase, and for patients the new method is cheaper, faster and more versatile than anything currently available.

“The method offers the possibility of personalizing the treatment and, given the possible precision, can potentially modify the current dosage needed for the patients, causing fewer side effects and making the treatments less expensive,”“Said Professor Hagemeyer.

Co-first author Dr Karen Alt, head of the nanotheranostics lab at the Australian Blood Disease Center at Monash University, says: “With only 0.01% of chemotherapy currently reaching cancerous tissue, this revolutionary new method can increase the potency of drugs reaching their target. “

“With over 80 different monoclonal antibodies approved for clinical use, this approach has enormous potential to improve these antibodies for the targeted delivery of diagnostic agents and therapeutic drugs. The objective is that ultimately the clinical translation of this technology improves the quality of life of patients suffering from serious diseases,“Said Dr Alt.

Journal reference

  1. Karen Alt, Self-assembly of nanocrystals with metallic-organic structure decorated with oriented antibodies for active targeting applications. Advanced Materials Paper DOI: 10.1002 / adma.202106607

About Shirley L. Kreger

Check Also

Modify the body’s immune system to help treat type 1 diabetes

In a new study, a team of researchers from the University of Missouri, Georgia Tech …